Schwab Shares Slide on Expanding Number of Orders
Charles Schwab (NYSE:SCHW), a leader in investing and trading with $10.76 trillion in total client assets that facilitated 7.6 million daily average trades in Q2 2025, today announced it has significantly expanded the list of securities available for trading overnight. These extended + overnight session orders (EXTO) are continuous orders that expire at 8pm ET each market day. With this expansion, all Schwab retail clients can now trade more than 1,100 securities 24 hours a day, five days a week (24/5), via the thinkorswim platform suite. The newly added securities, which are primarily exchange-traded funds (ETFs), are among the most popular and have been added in response to client demand and in alignment with Schwab’s criteria for overnight trading.Ameritrade, which was acquired by Schwab in 2020, pioneered 24/5 trading in 2018 as the first U.S. retail broker-dealer to make it available to traders, offering approximately two dozen ETFs in the overnight trading session. Schwab announced in February of this year that it had expanded the list of securities available in the overnight session to include the S&P 500 and NASDAQ-100 stocks, as well as hundreds of additional ETFs following a successful pilot of the expansion in Fall 2024.SCHW shares settled 33 cents to begin Monday trading at $95.47.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


